Prospective Randomized Trial for Postoperative Adjuvant Chemotherapy in Gastric Cancer without Serosal Invasion: Final Report
Journal of the Korean Gastric Cancer Association
;
: 257-262, 2004.
Article
in Korean
| WPRIM
| ID: wpr-157463
ABSTRACT
PUPOSE We reported our preliminary result in 2001. At that time, the follow-up period was too short to evaluate the survival benefit of adjuvant chemotherapy in gastric cancer without serosal invasion. Therefore, we followed those patients for 66 months to determine the long-term effects of adjuvant chemotherapy. MATERIALS AND METHODS:
We analyzed the recurrence pattern, the survival rate, and the disease-specific survival of 135 patients by reviewing their medical records and calling the patients or their relatives. All enrolled patients were included in the intention-to-treat analysis of efficacy.RESULTS:
The follow-up rate was 89.6% (121/135), and the median follow-up duration was 66 months. Among the 135 patients, 4 relapsed in group 1 (5-FU cisplatin), 7 in group 2 (mitomycin C oral 5-FU), and 6 in group 3 (oral 5-FU only). The overall survival rate was 89% in group 1, 84% in group 2, and 82% in group 3. There were no differences in the overall survival rates and the disease-specific survival rates among the three groups.CONCLUSION:
Oral chemotherapeutic agents have an acceptable effect for adjuvant chemotherapy compared with intravenous agent. However, a large-scale, prospective, randomized study, including a control group, is needed for an exact evaluation.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Recurrence
/
Stomach Neoplasms
/
Medical Records
/
Survival Rate
/
Prospective Studies
/
Follow-Up Studies
/
Chemotherapy, Adjuvant
/
Fluorouracil
Type of study:
Controlled clinical trial
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Journal of the Korean Gastric Cancer Association
Year:
2004
Type:
Article
Similar
MEDLINE
...
LILACS
LIS